Gilead’s 2023 Flat Sales Reflect Stagnation and COVID-19 Demand Decline
Gilead Sciences Inc. (NASDAQ: GILD) has reported a stagnant performance for the year 2023, with...
HIV / AIDS care
Gilead’s 2023 Stagnation Foresees Flat 2024 Sales as Veklury Revenues Dwindle
Gilead Sciences (NASDAQ: GILD) has reported a stagnant performance for 2023, with product sales remaining...
GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth...
Gilead’s Descovy Receives Additional Indication Approval from China’s NMPA for HIV-1 PrEP
Gilead Sciences, Inc. (NASDAQ: GILD), a major player in the pharmaceutical industry in the U.S.,...
Aidea Pharmaceutical Receives NMPA Approval to Clinically Test HIV-1 Treatment ACC017
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, has announced...
Jiangsu Aidea Pharmaceutical Partners with Fidson Healthcare for HIV/AIDS Treatments in Nigeria
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has reportedly entered into a strategic cooperation...
Gilead Reports Q3 2023 Financials with 1% YOY Revenue Increase and Updates 2023 Outlook
Gilead (NASDAQ: GILD) has released its financial results for the third quarter of 2023, showing...
GSK’s ViiV Healthcare Secures NMPA Approval for Vocabria in HIV-1 Treatment
UK pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has announced that its HIV joint venture, ViiV...
Jiangsu Aidea’s HIV-1 Drug ACC017 Accepted for NMPA Review in China
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...
Vela Diagnostics Partners with SRL Inc. to Expand Molecular Diagnostics in Japan
Singapore-based Vela Diagnostics, a global leader in integrated molecular solutions for diagnosing infectious diseases and...
Jiangsu Aidea Pharmaceutical Partners with National Medical Center for Infectious Disease on HIV Drug Development
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a...
Janssen Sues Distributors Over Counterfeit Antiretroviral Therapies in the US
Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, filed a lawsuit last week against pharmaceutical...
Jiangsu Aidea’s ACC008 Demonstrates Non-Inferior Efficacy to Genvoya in Phase III HIV Study
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced the summary report of a Phase...
EU Commits EUR 3 Million to Strengthen Healthcare Access in Latin America and Caribbean
The European Union (EU) has announced a EUR 3 million (USD 3.3 million) funding injection...
Ascletis Pharma’s ASC22 Combo Therapy Shows Promise in HIV Functional Cure Clinical Trial
China-based Ascletis Pharma Inc., (HKG: 1672) has announced that the Shanghai Public Health Clinical Center...
GSK’s Cabotegravir Receives NMPA Approval for HIV Treatment in China
The National Medical Products Administration (NMPA) has granted marketing approval for GlaxoSmithKline’s (GSK, NYSE: GSK)...
GSK Reports Q1 2023 Revenue Dip Amid COVID-19 Treatment Decline, Underlying Growth
UK-based multinational GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial results for the first...
Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine’s HIV Drugs
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a...
Immuno Cure BioTech Launches Phase I HIV/AIDS Vaccine Study
China-based Immuno Cure BioTech has announced the initiation of a Phase I clinical study for...
Cowell Health Partners with Gilead Sciences to Enhance Drug Accessibility
Cowell Health has announced a partnership with US-based Gilead Sciences, Inc., (NASDAQ: GILD) aimed at...